New Study Tests Cagrilintide and CagriSema for Childhood Obesity

Childhood and adolescent obesity and overweight are growing global health concerns, significantly increasing the risk of serious comorbidities like type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. Current treatment options for this vulnerable population are limited, highlighting an urgent need for effective and safe pharmacological interventions. This Phase 3 clinical trial aims to address the knowledge gap regarding the efficacy, safety, and pharmacokinetics of cagrilintide and CagriSema in children and adolescents.

As this study is currently RECRUITING participants, no direct findings are available yet; however, the trial is designed to rigorously evaluate specific outcomes. The primary endpoint is the percentage change in body weight from baseline to week 68. Researchers aim to observe a statistically significant reduction in body weight in the active treatment arms compared to placebo, with previous adult studies suggesting potential reductions of 15-20% for CagriSema over a similar duration. The study is powered to detect a clinically meaningful difference between treatment groups. The study's ultimate goal is to demonstrate that CagriSema (cagrilintide + semaglutide) leads to a superior and clinically meaningful weight loss, potentially exceeding 10% body weight reduction, compared to monotherapy or placebo in this young population. Secondary endpoints include the proportion of participants achieving 5%, 10%, and 15% body weight loss, as well as changes in BMI, waist circumference, and various cardiometabolic markers. Safety and tolerability will also be thoroughly assessed, monitoring for adverse events and their frequency across treatment groups.